期刊文献+

临床试验数据与安全监查委员会发展现状与操作规程 被引量:3

下载PDF
导出
摘要 临床试验数据与安全监查委员会(DSMB)是定期对临床研究累积数据进行分析与评价并提出建议的组织。其主要作用是确保研究的准确性和安全性…。DSMB的建立不仅能保护受试者的安全和利益,同时也能节约时间成本和资源。如何在临床试验中建立DSMB以及DSMB应该如何履行责任是临床研究所关心的问题。本研究介绍了DSMB的定义及发展,如何建立DSMB及DSMB与临床试验相关其他组织的区别。
出处 《中国医药》 2015年第2期286-288,共3页 China Medicine
基金 国家科技重大专项课题(2011ZX09304-07)
  • 相关文献

参考文献15

  • 1McLemore MR. The role of the data safety monitoring board : whywas the Avastin phase III clinical trial stopped. [ J]. Clin J OncolNurs, 2006,10(2) :153-154.
  • 2Armitage P. Interim analysis in clinical trials[ J]. Stat Med, 1991,10(6):925-935,936-937.
  • 3Dallas MJ. Accounting for interim safety monitoring of an adverse e-vent upon termination of a clinical trial [ J ]. J Biopharm Stat,2008,18(4) :631-638 ; discussion 439445.
  • 4Chow SC,Liu JP. Design and analysis of clinical trials : conceptsand methodologies [ M ]. 3rd edition. Hoboken : Wiley-Inter-science, 2008:422~435.
  • 5Hibberd PL, Weiner DL. Monitoring participant safety in phase Iand II interventional trials: options and controversies[ J]. J Inves-tig Med, 2004,52(7) :446452.
  • 6高灵灵,阎小妍,姚晨.临床试验数据监察委员会的操作规范和实践[J].中国新药杂志,2013,22(14):1667-1672. 被引量:7
  • 7高灵灵,阎小妍,姚晨.临床试验安全性监查过程中统计学方法的应用[J].中国新药杂志,2013,22(8):881-886. 被引量:3
  • 8Ellienberg SS,Fleming TR,DeMets DL. Data monitoring commit-tee in clinical trials : a practical perspective [ M ]. Hoboken : Wi-ley, 2002:119-147.
  • 9Guidance for Clinical Trial Sponsors:Establishment and Operationof Clinical Trial Data Monitoring Committees [ S]. US: Food andDrug Administration ,2006.
  • 10Dixon DO, Weiss S, Cahill K, et al. Data and safety monitoringpolicy for National Institute of Allergy and Infectious Diseases clini-cal trials[J]. Clin Trials, 2011,8(6) :727-735.

二级参考文献39

  • 1AdrianGrant,许群,乌正赉.提前终止临床试验 数据监测委员会可能具有重要作用[J].英国医学杂志中文版,2005,8(2):77-78. 被引量:1
  • 2CHOW SC, LIU JP. Design and analysis of clinical trials: con- cepts and methodologies [ M ]. Hoboken: Wiley-lnterscience, 2008.
  • 3PROSCHAN MA, LAN KKG, WITTES JT. Statistical monitoring of clinical trials: a unified approach [ M ]. New York: Springer Verlag, 2006.
  • 4SANKOH AJ. Interim analyses: an update of an FDA reviewer's experience and perspective[J].Drug lnf J, 1999,33 ( 1 ) : 165 - 176.
  • 5BALL G, PILLER LB, SILVERMAN MH. Continuous safety mo- nitoring for randomized controlled clinical trials with blinded treatment information. Part 1: ethical considerations [ J]. Cont- emp Clin Trials, 2011, 32 (S1): S2-S4.
  • 6BOLLAND K, WHITEHEAD J. Formal approaches to safety mo- nitoring of clinical trials in life - threatening conditions[ J ]. Stat Med, 2000, 19(21) : 2899 -2917.
  • 7HIBBERD PL, WEINER DL. Monitoring participant safety in phase I and II interventional trials: options and controversies [ J ]. J lnvestig Med, 2004,52 ( 7 ) :446 - 452.
  • 8GOLDMAN AI, HANNAN PJ. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm[J]. Stat Med, 2001,20( 11 ) :1575 - 1589.
  • 9ROBB MA, RACOOSIN JA, SHERMAN RE,et al. The US food and drug administration's sentinel initiative: expanding the hori- zons of medical product safety [ J ]. Pharmacoepidemiol Drug Saf, 2012, 21 (S1): S9-S11.
  • 10ELLENBERG SS, FLEMING TR, DEMETS DL. Data monitoring committees in clinical trials : a practical perspective[ M ]. Chich- ester: Wiley, 2002.

共引文献14

同被引文献43

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部